INTRODUCTION
============

Systemic lupus erythematosus (SLE) is a chronic autoimmune disease characterized by multisystem inflammation commonly including the skin, kidneys, and joints, and other systems. While the pathogenesis of SLE is not completely understood, it seems likely that both genetic and environmental factors contribute to the disease. A number of genetic factors have been associated with SLE in recent years ([@B11]; [@B9]), providing a window into human disease pathogenesis. Interestingly, many of these genetic variations associated with risk of SLE have function within the type I interferon (IFN) pathway ([@B9]). Type I IFN is a classical anti-viral molecule which causes activation of antigen presenting cells within the innate immune system and increased expression of MHC and co-stimulatory molecules ([@B42]).

Many lines of evidence support the idea that type I IFN plays a primary role in SLE pathogenesis ([@B35]). Circulating type I IFN levels are elevated in many SLE patients ([@B58]), and this elevation is also observed in unaffected members of SLE families, suggesting that high IFN levels are a heritable risk factor for SLE ([@B38]). Familial aggregation has been observed with other cytokines in SLE, such as tumor necrosis factor alpha and IL-10 ([@B10]; [@B28]), but in these cases unrelated family members such as spouses shared the trait as well, suggesting a contribution from environmental factors. Subsequent study of SLE-associated genetic factors has confirmed that SLE-risk genes contribute to the high IFN levels observed in SLE ([@B16]; [@B18]; [@B1]; [@B39]), and it seems that the high IFN trait is significantly polygenic ([@B12]; [@B17]; [@B21]; [@B14]). The genetic data all support the concept that common gain-of-function variations in the type I IFN pathway are associated with SLE pathogenesis. Additionally, rare variants in the TREX1 gene have been described that are strongly associated with a SLE and Aicardi-Goutieres syndrome, a rare condition characterized by alterations in type I IFN and neurologic symptoms ([@B24]; [@B33]). Recombinant human type I IFN has been administered as a therapeutic to treat some malignancies and chronic viral infection, and in some cases *de novo* SLE has developed ([@B48]), which typically resolves when the type I IFN is stopped ([@B40]). These data taken together support the idea that type I IFN is a primary pathogenic factor in human SLE. While there are significant differences in SLE incidence between men and women (9:1 female), type I IFN pathway activation seems to be equal between men and women with SLE ([@B36]; [@B59]). There is an increased incidence of SLE in African-Americans as compared to European-American populations (4:1), and in this case is seems that there are some differences in the way the pathway is activated, but high IFN is clearly seen in both populations ([@B19], [@B20]). Thus type I IFN is a common pathway to SLE susceptibility, and it follows that molecules operating upstream of type I IFN production would play a role in disease. A large body of work has supports the relevance of the endosomal Toll-like receptors in SLE pathogenesis ([@B26]; [@B50]). In this review, we will focus on emerging data which implicates RNA helicases in type I IFN pathway dysregulation in human SLE. These data may also be relevant to other autoimmune diseases, as a number of conditions have been associated with increased type I IFN, including dermatomyositis, Sjogren's syndrome, neuromyelitis optica, and others ([@B37], [@B41]; [@B57]; [@B5]; [@B29]). In particular, we will focus on known functional genetic polymorphisms in the IFIH1 (MDA5) and mitochondrial antiviral signaling protein (MAVS) genes which function in helicase pathways, and have been implicated in human SLE.

PATTERN RECOGNITION RECEPTORS INVOLVED IN ANTI-VIRAL RESPONSES AND SLE
======================================================================

Several families of receptors that recognize pathogen-associated molecular patterns (PAMPs) have been described, such as the Toll-like receptors (TLRs) and retinoic acid-inducible gene I (RIG-I)-like receptor (RLRs). TLRs are transmembrane receptors expressed in specific immune cells, such as dendritic cells and macrophages. TLR7, 8, and 9 are expressed in the endosomal membrane, and can recognize viral nucleic acid. In anti-viral immunity, viral immune complexes are taken up via Fc receptors, and then delivered to the endosome resulting in TLR activation. RLRs, on the other hand, are cytosolic proteins that can recognize viral nucleic acid in the cytosol. Activation of either TLRs or RLRs results in IFN production and an anti-viral response (**Figure [1](#F1){ref-type="fig"}**).

![**Diagram of nucleic acid sensing antiviral immune response pathways.** IFN, type I interferon; IL, interleukin; IRF, interferon regulatory factor; LGP2, laboratory of genetics and physiology 2; MAVS, mitochondrial antiviral signaling protein; MDA5, melanoma differentiation-associated gene 5; MyD88, myeloid differentiation primary response gene 88; NF-κB, nuclear factor-κB; RIG-I, retinoic acid-inducible gene I; TLR, Toll-like receptor; TNF, tumor necrosis factor; TRIF, Toll/IL-1R-domain-containing adaptor inducing interferon β.](fgene-05-00418-g001){#F1}

The endosomal TLRs have been implicated in SLE pathogenesis in a number of previous studies. Genetic variations in TLR7 are associated with SLE susceptibility in humans ([@B3]). Mice which carry a duplication of the endosomal TLR region of the X-chromosome have enhanced susceptibility to an SLE-like disease ([@B55]). Interestingly, the autoantibodies which are characteristically produced in SLE target components of the cell nucleus, for example antibodies against double-stranded DNA and nuclear RNA-binding proteins. These SLE-associated autoantibodies form immune complexes that contain RNA and DNA, and the immune complexes can result in activation of the TLR system with subsequent type I IFN production ([@B26], [@B27]). Thus, the anti-nuclear immune response that characterizes SLE produces immune complexes that are viral mimics, subverting normal viral immunity. These autoantibodies are frequently high titer and continuously present in SLE, and the antigens are ubiquitous, resulting in consistent inappropriate activation of the type I IFN pathway in SLE ([@B50]). Supporting this idea, one of the accepted and effective treatments for SLE, hydroxychloroquine, seems to interrupt endosomal TLR signaling ([@B22]; [@B49]).

RNA HELICASES
=============

Ribonucleic acid helicases are involved in almost all cellular processes involving RNA ([@B53]). These enzymes use ATP to bind or remodel RNA and RNA--protein complexes ([@B25]). Based on their shared conserved motifs and three dimensional core structures, RNA helicases are grouped into families and superfamilies ([@B25]; [@B53]). The majority of RNA helicases belong to superfamily 2 (SF2; [@B45]; [@B53]). DEAD box proteins are the largest family of helicases in SF2, and in humans these helicases have essential physiological roles in cellular RNA metabolism ([@B25]). The DEAD box helicases work by destabilizing short RNA duplexes close to the binding site of the helicase. In contrast, the DExH group of helicases work in a progressive fashion, unwinding longer stretches of RNA ([@B45]). DEAD box helicases frequently play a role in viral immunity by acting as sensors cytosolic viral nucleic acids. Besides the RLR DEAD box helicases which include RIG-I, MDA5, and LGP2, other DEAD box helicases likely perform this role as well, including DDX1, DDX3, DDX36, DDX41, DDX60, and others ([@B6]). In addition to sensing nucleic acid, some of these functions may be helicases further downstream in the pattern recognition receptor signaling pathways, potentially playing roles in transcriptional regulation ([@B6]). Interestingly, it appears that some RNA helicases are important for viral replication, suggesting that viruses have adopted this cellular mechanism to their own advantage in some cases ([@B6]).

Retinoic acid-inducible gene-I and MDA5 are proteins encoded by the DDX58 and IFIH1 genes, respectively. These RLRs are induced by type I IFN, and each recognize specific types of viruses ([@B60]). RIG-I and MDA5 recognize distinct viral RNA structures containing 5′ triphosphate in single and double-stranded RNA ([@B51]). These two RLRs demonstrate some specificity in the types of nucleic acids they recognize: while MDA5 senses picornavirus-derived nucleic acid, RIG-I senses other viral nucleic acids, such as those derived from influenza A ([@B60]). This differential recognition is based on the distinct RNA patterns generated by different viruses ([@B60]).

Activation of RIG-I and MDA5 by nucleic acid leads to binding of the mitochondrial adaptor IFN β promoter stimulater 1 (IPS-1) also known as MAVS ([@B46]). As the name suggests, MAVS is found in the mitochondrial membrane, and is critical to signal transduction via MDA5 and RIG-I. MAVS forms large multimeric polymers on the mitochondrial membrane in combination with RIG-I and MDA5 bound to target nucleic acids, forming an active signaling complex ([@B46]). This leads to activation of NF-κB, IRF3, and IRF7 ([@B46]). These transcription factors are involved in IFN and interferon-stimulated gene expression, and the production of type-1 IFN and pro-inflammatory cytokines ([@B51]; **Figure [1](#F1){ref-type="fig"}**).

MDA5/IFIH1
==========

IFIH1 is the gene that encodes MDA5, and a common coding-change polymorphism in the IFIH1 gene has been associated with risk of SLE and other autoimmune diseases in humans ([@B52]; [@B56]; [@B11]; [@B8]; [@B54]; [@B32]). This A946T polymorphism in IFIH1 was identified in case-control genetic studies of SLE ([@B11]; [@B8]), and interestingly this polymorphism was the major finding in a recent admixture-mapping genetic screen to identify genes associated with SLE in African-Americans ([@B32]), supporting relevance of this polymorphism across multiple ancestral backgrounds. This polymorphism appears to be gain-of-function in nature, being associated with increased IFIH1 mRNA expression ([@B4]), increased sensitivity to type I IFN and increased IFN-induced gene expression in circulating blood cells from SLE patients ([@B47]), and modulation of inflammation- and apoptosis-related gene expression ([@B32]). These studies support the general idea that over-activity of the anti-viral helicases would result in greater type I IFN signaling and risk of SLE. Rare loss-of-function variations in IFIH1 have been discovered in the IFIH1 gene, and interestingly these loss-of-function variants appear to be protective against autoimmune disease ([@B34]), further supporting the idea that increased function of IFIH1/MDA5 is associated with risk of autoimmune disease.

Studies in mice have also supported this hypothesis. A recent study demonstrated that a single coding-change mutation in IFIH1 (Gly821Ser) generated by *N*-ethyl-*N*-nitrosourea (ENU) resulted in constitutive activation of MDA5 ([@B7]). Mice with this mutation developed a systemic autoimmune disease similar to lupus, with nephritis characterized by lymphocyte infiltration as well as deposition of immunoglobulin and complement, systemic inflammation in the heart and lung, and increased tumor necrosis factor alpha, IL-6 and type I IFN ([@B7]). This gain-of-function mutation in the mouse line has not been observed in humans, but it supports the general concept that gain of function in IFIH1 is associated with autoimmunity.

MAVS
====

Genetic studies in human SLE have also identified a functional coding-change polymorphism in MAVS, a key adapter of both the RIG-I and MDA5 helicases. The C97F polymorphism in MAVS substantially reduced the expression of type I IFN and other proinflammatory mediators in human cell lines ([@B44]). Interestingly, this variation was almost exclusively found in the African-American population, with a frequency of 10.2% in controls ([@B44]). In African--American patients with SLE, the C79F allele was associated with low type I IFN and was more than twice as common (22.4% frequency) in SLE patients who lacked autoantibodies to RNA-binding proteins. This study demonstrated that a coding-change genetic variation in the gene encoding MAVS has a functional impact on the antiviral IFN pathway in humans, and is associated with a serologic subgroup of SLE patients ([@B44]). These studies in both MAVS and IFIH1 demonstrate the importance of variations in these genes upon immune function and autoimmune disease risk in human populations.

CONCLUSION
==========

Dysregulation of anti-viral helicase immune responses represent a primary pathogenic factor in human SLE. This is demonstrated by the presence of coding-change polymorphisms in both the IFIH1 and MAVS genes which modulate function of the type I IFN pathway and risk of SLE in humans. While immune complexes formed by SLE autoantibodies and nuclear material seem to be the likely trigger for endosomal TLR stimulation in SLE, the exact triggers of the cytosolic anti-viral helicases in human SLE are somewhat less clear. Viruses may stimulate some of the early events in SLE patients, as strong epidemiological data implicates Epstein--Barr virus infection in the initial pathogenesis of SLE ([@B13]; [@B43]). It is possible that this represents a gene -- environment interaction in human SLE -- a hypersensitive or overactive anti-viral helicase system coupled with a viral trigger, such as Epstein--Barr virus infection, which then results in an exaggerated type I IFN response and subsequent misdirection of the adaptive immune response against self-antigens. It is also possible that viral-like elements, such as LINE elements, may also play a role in the chronic stimulation of these cytosolic nucleic acid receptors ([@B2]). Both Epstein-Barr virus and LINE-1 RNAs could potentially be seen as "foreign" by the cytosolic helicases. The fact that both the TLR and cytosolic pathways of viral recognition are involved in human SLE and the convergence of these pathways upon type I IFN and anti-viral responses is striking, suggesting that over-active anti-viral immunity represents a major common pathogenic pathway in human SLE. A number of therapeutics have been developed to target type I IFN in SLE, including monoclonal antibodies against IFN-α ([@B31]; [@B15]; [@B30]), as well as a vaccination strategy aimed at inducing antibodies against IFN-α ([@B23]). These studies are in early stages, phase I to phase II, and thus far the data generally support relative safety and proof-of-mechanism. It is too early to make conclusions about efficacy, but some of the larger phase II studies have reported potential subset effects within the overall SLE patient groups ([@B15]). This would suggest that anti-IFN therapies may not work for every patient, but the genetics data we discuss in this review may also suggest this outcome. It seems that the IFN pathway is impacted by a number of genetic factors, and these factors will not be shared by all patients. Therapeutics targeting the RNA helicases could be potentially interesting in SLE, and further understanding of the specific dysregulation of the helicase pathways in human SLE such as the work summarized in this review could help to determine optimal points of intervention in the pathway and in which group of patients.
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